SSY Group Wins Hebei Approval for New Inflammation and Cardiovascular Diagnostic Test Kits

The latest announcement is out from SSY Group ( (HK:2005) ).

SSY Group Limited has received medical device registration certificates from the Hebei Provincial Drug Administration for two new diagnostic products: a full-range C-reactive protein test kit and a Serum Amyloid A/C-reactive protein test kit, both based on fluorescent immunochromatography technology. These test kits are designed for in vitro quantitative detection of biomarkers in human blood components, serving as adjunct tools in diagnosing non-specific inflammation and, in the case of the full-range CRP kit, cardiovascular diseases, marking a further build-out of the group’s medical device product line.

The company notes that successive approvals of multiple test kits are opening a new growth track for its medical device business, signalling a strategic deepening into the in vitro diagnostics segment. This development may enhance SSY Group’s competitiveness in China’s healthcare market by broadening its diagnostic offerings for hospitals and clinics, with potential long-term benefits for shareholders and healthcare stakeholders as the product suite scales.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the medical and healthcare sector, focusing on the development and production of medical devices and diagnostic test kits for clinical use in China. The company’s portfolio is expanding into in vitro diagnostic products aimed at supporting the diagnosis of inflammation and cardiovascular-related conditions, strengthening its position in the domestic medical device market.

Average Trading Volume: 9,836,963

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.76B

For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.